Teva plant tagged with warning letter for issues making schizophrenia drug

Teva production
The FDA has issued a warning letter to a Teva plant in Florida that using laser drilling to manufacture its paliperidone extended-release tablets.(Teva)

For years now, Teva has had difficulty with the laser drilling of a schizophrenia drug so that patients get the right dose. The FDA, having finally tired of the company being unable to resolve the issues, has now slapped the plant in Florida with a warning letter.

The letter, posted Tuesday, acknowledges the company has already taken the agency’s advice to use an outside consultant, but faults it for repeat violations of problems pointed out during inspections of the Davie, Florida plant in 2013, 2016, 2017 and then again last year.

“These repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate,” the FDA said.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

A Teva spokeswoman in an email today said, “We are working closely with FDA to address its inspection-related concerns as quickly as possible.”

RELATED: Teva's stunning list of cuts targets 14K jobs, $3B in costs and plants around the globe

According to the warning letter, the problems at the Actavis plant in Davie predate, Teva’s $40.5 billion purchase of Allergan’s generics business in 2016. But the issues have continued for several years since, resulting in a recall of the paliperidone extended-release tablets in 2017, which started at the retail level but was then extended to the consumer level.

The company at the time acknowledged the dissolution issues tied to faulty laser drilling could reduce the drug’s effectiveness at treating a patient’s symptoms, “including suicidal thoughts and behavior, self-injurious behavior, mental hospitalizations, assaults, aggressive behavior, as well as vocal and motor tics.”

During a visit in August 2018, the FDA found issues with the visual inspection system and faulted the plant for not thoroughly investigating problems to find their cause, or of instituting fixes quickly enough. It raised questions about whether a single quality assurance inspector per shift would be able validate the “presence of a laser drilled hole that can be as small as 0.3mm" coming off the production line. The letter did not specify how many tablets that would be but when Actavis invested $40 million into the plant in 2013, it reported the facility produced about 2.2 billion immediate and extended-release units annually.

The buyout of Actavis in which Teva got the plant continues to be a drag on the Israel-based company. Last month Teva reported that 2019 would be more challenging than expected as generics eat away sales of its blockbuster multiple sclerosis drug Copaxone. The company forecast 2019 revenues between $17 billion and $17.4 billion, missing consensus forecasts of more than $18 billion. And it’s expecting non-GAAP earnings per share of $2.20 to $2.50 versus the consensus estimate of $2.77.

Suggested Articles

The FDA is allowing some drugmakers to exceed the level of risk from a probable cancer-causing impurity in losartan for six months.

The FDA hit United Exchange Corp. with a warning letter, citing the company for a number of “significant” violations with its quality control systems.

With a deal for the digoxin portfolio of Poland's Nobilus, C2 Pharma will have two supplies of API for making the sometimes difficult-to-get drug.…